Skip to main content
. Author manuscript; available in PMC: 2017 Feb 14.
Published in final edited form as: Ocul Immunol Inflamm. 2016 Apr 12;25(1):52–61. doi: 10.3109/09273948.2016.1158276

FIGURE 6.

FIGURE 6

Association of infliximab treatment duration with change in cytokine production after infliximab treatment in BD patients. Correlation of infliximab treatment duration (months) with change in individual cytokine production by 5 g/mL IRBP-stimulated PBMCs of BD patients was analyzed by Pearson’s correlation coefficient test: (A) IL-1β (y = −22.3 + 1.29x, R2 = 0.18, p = 0.298); (B) IL-4 (y = 71.7−1.49x, R2 = 0.5789, p = 0.028); (C) IL-6 (y = −21.5 + 1.06x, R2 = 0.244, p = 0.213); (D) IL-10 (y = 18.8 + 0.25x, R2 = 0.089, p = 0.472); (E) IL-17A (y = −21.0 + 0.72x, R2 = 0.043, p = 0.623); (F) IL-17F (y = 12.4 + 0.63x, R2 = 0.267, p = 0.190); (G) IL-21 (y = −85.0 + 3.36x, R2 = 0.820, p = 0.279); (H) IL-22 (y = 33.3 + 0.33x, R2 = 0.061, p = 0.554); (I) IL-31 (y = 20.2 + 0.46x, R2 = 0.121, p = 0.399); (J) IFN-γ (y = 22.0 + 0.66x, R2 = 0.146, p = 0.350); (K) sCD40L (y = 17.2 + 0.43x, R2 = 0.061, p = 0.557); and (L) TNFα (y = −31.2 + 1.36x, R2 = 0.297, p = 0.162). Change in cytokine production = level of cytokine before infliximab infusion – level of cytokine after infliximab infusion/level of cytokine before infliximab infusion × 100%.